Charities renew investment in type 1 diabetes research collaboration15 Jul 2019
Diabetes UK and JDRF have announced their continued commitment to revolutionising Type 1 diabetes treatment, by awarding £490,000 to fund the next generation of immunotherapy research. The Type 1 Diabetes UK Immunotherapy Consortium (T1D UK) was set up in 2015 with major funding from Diabetes UK & the JDRF, to promote, develop and support immunotherapy research in T1D. With the renewal of funding, the next phase of the Consortium would plan to:
- Expand their network of research sites so that 50% of the UK population will live within 50 miles of a site, with the aim of recruiting 200 newly diagnosed children and 150 adults into trials each year;
- Harmonise protocols across immunotherapy trials in order to reduce variation and facilitate the pooling of data between different trials so that scientists can learn even more and finally;
- Make each trial more efficient, so they can be conducted in half the time and with half the number of volunteers.
Professor Colin Dayan, DRU Cymru work package lead for Immunity and Type 1 Diabetes, leads T1D UK’s network of research centres. He explained: “Insulin is too difficult. It’s a blessing we have it because it keeps people with type 1 diabetes alive – people were dying very quickly 100 years ago. But it’s also a curse because it’s so difficult to use – and this is what people with type 1 are facing every day for the rest of their lives... We will focus on making immunotherapy research bigger, smarter and faster. We plan to increase the number of clinical trials being run in the UK and make each trial more efficient, so they can be conducted in half the time and with half the number of volunteers. This will enable us to collect the evidence required to get a drug licensed, and made available in the diabetes clinic, sooner than is currently possible.”